The NF1 somatic mutational landscape in sporadic human cancers
Neurofibromatosis type 1 (NF1: Online Mendelian Inheritance in Man (OMIM) #162200) is an autosomal dominantly inherited tumour predisposition syndrome. Heritable constitutional mutations in the NF1 gene result in dysregulation of the RAS/MAPK pathway and are causative of NF1. The major known functio...
Saved in:
| Published in | Human genomics Vol. 11; no. 1; pp. 13 - 19 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central
21.06.2017
BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Neurofibromatosis type 1 (NF1: Online Mendelian Inheritance in Man (OMIM) #162200) is an autosomal dominantly inherited tumour predisposition syndrome. Heritable constitutional mutations in the NF1 gene result in dysregulation of the RAS/MAPK pathway and are causative of NF1. The major known function of the NF1 gene product neurofibromin is to downregulate RAS. NF1 exhibits variable clinical expression and is characterized by benign cutaneous lesions including neurofibromas and café-au-lait macules, as well as a predisposition to various types of malignancy, such as breast cancer and leukaemia. However, acquired somatic mutations in NF1 are also found in a wide variety of malignant neoplasms that are not associated with NF1.
Capitalizing upon the availability of next-generation sequencing data from cancer genomes and exomes, we review current knowledge of somatic NF1 mutations in a wide variety of tumours occurring at a number of different sites: breast, colorectum, urothelium, lung, ovary, skin, brain and neuroendocrine tissues, as well as leukaemias, in an attempt to understand their broader role and significance, and with a view ultimately to exploiting this in a diagnostic and therapeutic context.
As neurofibromin activity is a key to regulating the RAS/MAPK pathway, NF1 mutations are important in the acquisition of drug resistance, to BRAF, EGFR inhibitors, tamoxifen and retinoic acid in melanoma, lung and breast cancers and neuroblastoma. Other curiosities are observed, such as a high rate of somatic NF1 mutation in cutaneous melanoma, lung cancer, ovarian carcinoma and glioblastoma which are not usually associated with neurofibromatosis type 1. Somatic NF1 mutations may be critical drivers in multiple cancers. The mutational landscape of somatic NF1 mutations should provide novel insights into our understanding of the pathophysiology of cancer. The identification of high frequency of somatic NF1 mutations in sporadic tumours indicates that neurofibromin is likely to play a critical role in development, far beyond that evident in the tumour predisposition syndrome NF1. |
|---|---|
| AbstractList | Neurofibromatosis type 1 (NF1: Online Mendelian Inheritance in Man (OMIM) #162200) is an autosomal dominantly inherited tumour predisposition syndrome. Heritable constitutional mutations in the NF1 gene result in dysregulation of the RAS/MAPK pathway and are causative of NF1. The major known function of the NF1 gene product neurofibromin is to downregulate RAS. NF1 exhibits variable clinical expression and is characterized by benign cutaneous lesions including neurofibromas and café-au-lait macules, as well as a predisposition to various types of malignancy, such as breast cancer and leukaemia. However, acquired somatic mutations in NF1 are also found in a wide variety of malignant neoplasms that are not associated with NF1.
Capitalizing upon the availability of next-generation sequencing data from cancer genomes and exomes, we review current knowledge of somatic NF1 mutations in a wide variety of tumours occurring at a number of different sites: breast, colorectum, urothelium, lung, ovary, skin, brain and neuroendocrine tissues, as well as leukaemias, in an attempt to understand their broader role and significance, and with a view ultimately to exploiting this in a diagnostic and therapeutic context.
As neurofibromin activity is a key to regulating the RAS/MAPK pathway, NF1 mutations are important in the acquisition of drug resistance, to BRAF, EGFR inhibitors, tamoxifen and retinoic acid in melanoma, lung and breast cancers and neuroblastoma. Other curiosities are observed, such as a high rate of somatic NF1 mutation in cutaneous melanoma, lung cancer, ovarian carcinoma and glioblastoma which are not usually associated with neurofibromatosis type 1. Somatic NF1 mutations may be critical drivers in multiple cancers. The mutational landscape of somatic NF1 mutations should provide novel insights into our understanding of the pathophysiology of cancer. The identification of high frequency of somatic NF1 mutations in sporadic tumours indicates that neurofibromin is likely to play a critical role in development, far beyond that evident in the tumour predisposition syndrome NF1. Abstract Background Neurofibromatosis type 1 (NF1: Online Mendelian Inheritance in Man (OMIM) #162200) is an autosomal dominantly inherited tumour predisposition syndrome. Heritable constitutional mutations in the NF1 gene result in dysregulation of the RAS/MAPK pathway and are causative of NF1. The major known function of the NF1 gene product neurofibromin is to downregulate RAS. NF1 exhibits variable clinical expression and is characterized by benign cutaneous lesions including neurofibromas and café-au-lait macules, as well as a predisposition to various types of malignancy, such as breast cancer and leukaemia. However, acquired somatic mutations in NF1 are also found in a wide variety of malignant neoplasms that are not associated with NF1. Main body Capitalizing upon the availability of next-generation sequencing data from cancer genomes and exomes, we review current knowledge of somatic NF1 mutations in a wide variety of tumours occurring at a number of different sites: breast, colorectum, urothelium, lung, ovary, skin, brain and neuroendocrine tissues, as well as leukaemias, in an attempt to understand their broader role and significance, and with a view ultimately to exploiting this in a diagnostic and therapeutic context. Conclusion As neurofibromin activity is a key to regulating the RAS/MAPK pathway, NF1 mutations are important in the acquisition of drug resistance, to BRAF, EGFR inhibitors, tamoxifen and retinoic acid in melanoma, lung and breast cancers and neuroblastoma. Other curiosities are observed, such as a high rate of somatic NF1 mutation in cutaneous melanoma, lung cancer, ovarian carcinoma and glioblastoma which are not usually associated with neurofibromatosis type 1. Somatic NF1 mutations may be critical drivers in multiple cancers. The mutational landscape of somatic NF1 mutations should provide novel insights into our understanding of the pathophysiology of cancer. The identification of high frequency of somatic NF1 mutations in sporadic tumours indicates that neurofibromin is likely to play a critical role in development, far beyond that evident in the tumour predisposition syndrome NF1. Neurofibromatosis type 1 (NF1: Online Mendelian Inheritance in Man (OMIM) #162200) is an autosomal dominantly inherited tumour predisposition syndrome. Heritable constitutional mutations in the NF1 gene result in dysregulation of the RAS/MAPK pathway and are causative of NF1. The major known function of the NF1 gene product neurofibromin is to downregulate RAS. NF1 exhibits variable clinical expression and is characterized by benign cutaneous lesions including neurofibromas and café-au-lait macules, as well as a predisposition to various types of malignancy, such as breast cancer and leukaemia. However, acquired somatic mutations in NF1 are also found in a wide variety of malignant neoplasms that are not associated with NF1.BACKGROUNDNeurofibromatosis type 1 (NF1: Online Mendelian Inheritance in Man (OMIM) #162200) is an autosomal dominantly inherited tumour predisposition syndrome. Heritable constitutional mutations in the NF1 gene result in dysregulation of the RAS/MAPK pathway and are causative of NF1. The major known function of the NF1 gene product neurofibromin is to downregulate RAS. NF1 exhibits variable clinical expression and is characterized by benign cutaneous lesions including neurofibromas and café-au-lait macules, as well as a predisposition to various types of malignancy, such as breast cancer and leukaemia. However, acquired somatic mutations in NF1 are also found in a wide variety of malignant neoplasms that are not associated with NF1.Capitalizing upon the availability of next-generation sequencing data from cancer genomes and exomes, we review current knowledge of somatic NF1 mutations in a wide variety of tumours occurring at a number of different sites: breast, colorectum, urothelium, lung, ovary, skin, brain and neuroendocrine tissues, as well as leukaemias, in an attempt to understand their broader role and significance, and with a view ultimately to exploiting this in a diagnostic and therapeutic context.MAIN BODYCapitalizing upon the availability of next-generation sequencing data from cancer genomes and exomes, we review current knowledge of somatic NF1 mutations in a wide variety of tumours occurring at a number of different sites: breast, colorectum, urothelium, lung, ovary, skin, brain and neuroendocrine tissues, as well as leukaemias, in an attempt to understand their broader role and significance, and with a view ultimately to exploiting this in a diagnostic and therapeutic context.As neurofibromin activity is a key to regulating the RAS/MAPK pathway, NF1 mutations are important in the acquisition of drug resistance, to BRAF, EGFR inhibitors, tamoxifen and retinoic acid in melanoma, lung and breast cancers and neuroblastoma. Other curiosities are observed, such as a high rate of somatic NF1 mutation in cutaneous melanoma, lung cancer, ovarian carcinoma and glioblastoma which are not usually associated with neurofibromatosis type 1. Somatic NF1 mutations may be critical drivers in multiple cancers. The mutational landscape of somatic NF1 mutations should provide novel insights into our understanding of the pathophysiology of cancer. The identification of high frequency of somatic NF1 mutations in sporadic tumours indicates that neurofibromin is likely to play a critical role in development, far beyond that evident in the tumour predisposition syndrome NF1.CONCLUSIONAs neurofibromin activity is a key to regulating the RAS/MAPK pathway, NF1 mutations are important in the acquisition of drug resistance, to BRAF, EGFR inhibitors, tamoxifen and retinoic acid in melanoma, lung and breast cancers and neuroblastoma. Other curiosities are observed, such as a high rate of somatic NF1 mutation in cutaneous melanoma, lung cancer, ovarian carcinoma and glioblastoma which are not usually associated with neurofibromatosis type 1. Somatic NF1 mutations may be critical drivers in multiple cancers. The mutational landscape of somatic NF1 mutations should provide novel insights into our understanding of the pathophysiology of cancer. The identification of high frequency of somatic NF1 mutations in sporadic tumours indicates that neurofibromin is likely to play a critical role in development, far beyond that evident in the tumour predisposition syndrome NF1. Background Neurofibromatosis type 1 (NF1: Online Mendelian Inheritance in Man (OMIM) #162200) is an autosomal dominantly inherited tumour predisposition syndrome. Heritable constitutional mutations in the NF1 gene result in dysregulation of the RAS/MAPK pathway and are causative of NF1. The major known function of the NF1 gene product neurofibromin is to downregulate RAS. NF1 exhibits variable clinical expression and is characterized by benign cutaneous lesions including neurofibromas and cafe-au-lait macules, as well as a predisposition to various types of malignancy, such as breast cancer and leukaemia. However, acquired somatic mutations in NF1 are also found in a wide variety of malignant neoplasms that are not associated with NF1. Main body Capitalizing upon the availability of next-generation sequencing data from cancer genomes and exomes, we review current knowledge of somatic NF1 mutations in a wide variety of tumours occurring at a number of different sites: breast, colorectum, urothelium, lung, ovary, skin, brain and neuroendocrine tissues, as well as leukaemias, in an attempt to understand their broader role and significance, and with a view ultimately to exploiting this in a diagnostic and therapeutic context. Conclusion As neurofibromin activity is a key to regulating the RAS/MAPK pathway, NF1 mutations are important in the acquisition of drug resistance, to BRAF, EGFR inhibitors, tamoxifen and retinoic acid in melanoma, lung and breast cancers and neuroblastoma. Other curiosities are observed, such as a high rate of somatic NF1 mutation in cutaneous melanoma, lung cancer, ovarian carcinoma and glioblastoma which are not usually associated with neurofibromatosis type 1. Somatic NF1 mutations may be critical drivers in multiple cancers. The mutational landscape of somatic NF1 mutations should provide novel insights into our understanding of the pathophysiology of cancer. The identification of high frequency of somatic NF1 mutations in sporadic tumours indicates that neurofibromin is likely to play a critical role in development, far beyond that evident in the tumour predisposition syndrome NF1. |
| ArticleNumber | 13 |
| Author | Tovell, Hannah Upadhyaya, Meena Philpott, Charlotte Cooper, David N. Frayling, Ian M. |
| Author_xml | – sequence: 1 givenname: Charlotte surname: Philpott fullname: Philpott, Charlotte – sequence: 2 givenname: Hannah surname: Tovell fullname: Tovell, Hannah – sequence: 3 givenname: Ian M. surname: Frayling fullname: Frayling, Ian M. – sequence: 4 givenname: David N. surname: Cooper fullname: Cooper, David N. – sequence: 5 givenname: Meena surname: Upadhyaya fullname: Upadhyaya, Meena |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28637487$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Ustq3TAQFSUlj9t8QDfF0E03bvWyHptACUkbCO0mXYuRLOf6Ylu3kl3o32cSpyHJoqBhhtGZwzzOCTmY0hQJec_oZ8aM-lIk5VLVlGk0amvxhhwzqW2thZIHz-IjclLKjlLBhJaH5IgbhYHRx-TsZhurH5esKmmEuQ_VuMzo0wRDNcDUlgD7WPVTVfYpQ4uA7TLCVAWYQszlHXnbwVDi6aPfkF-XFzfn3-vrn9-uzr9e10EpOtfB2mCpt4YbYZkJVFppI2-DipY3gBE3XUN1VEK0SnPqfae5CqbRHUgIYkOuVt42wc7tcz9C_usS9O4hkfKtg4ztD9FBx8F4HllDmfRUeR9aJkznuaVGGoZcZyvXfvFjbEOc5gzDC9KXP1O_dbfpj2ukoYxLJPj0SJDT7yWW2Y19CXHAfcW0FMcs4wpfwxH68RV0l5aMy31ANQrnRduQD887emrl35kQwFZAyKmUHLsnCKPuXgpulYJDKbh7KTiBNfpVTejX0-JQ_fCfyju-57YN |
| CitedBy_id | crossref_primary_10_1016_j_cancergen_2025_01_005 crossref_primary_10_1111_his_13856 crossref_primary_10_17650_2313_805X_2021_8_1_17_25 crossref_primary_10_3389_fonc_2022_926967 crossref_primary_10_3389_fonc_2019_01289 crossref_primary_10_3390_dermatopathology11010005 crossref_primary_10_1016_j_trecan_2019_07_004 crossref_primary_10_3390_cancers12103066 crossref_primary_10_1101_cshperspect_a031500 crossref_primary_10_1093_nar_gkab626 crossref_primary_10_1016_j_cellsig_2023_110879 crossref_primary_10_1016_S0021_9258_17_49919_4 crossref_primary_10_3389_fmolb_2021_784876 crossref_primary_10_1089_dna_2022_0552 crossref_primary_10_3390_ijms252211954 crossref_primary_10_1038_s10038_023_01188_4 crossref_primary_10_3390_cancers14102377 crossref_primary_10_1158_2159_8290_CD_20_1114 crossref_primary_10_1016_j_ctrv_2020_102070 crossref_primary_10_1136_bcr_2018_224744 crossref_primary_10_1002_ski2_394 crossref_primary_10_1002_pmic_201800334 crossref_primary_10_1093_ejendo_lvae077 crossref_primary_10_1007_s10689_020_00184_3 crossref_primary_10_1016_j_cancergen_2022_07_004 crossref_primary_10_1007_s10689_023_00355_y crossref_primary_10_1002_ajmg_a_61112 crossref_primary_10_1111_apm_13187 crossref_primary_10_18632_oncotarget_26677 crossref_primary_10_3390_ijms24010859 crossref_primary_10_1074_jbc_RA119_010934 crossref_primary_10_3390_cancers11040448 crossref_primary_10_1002_ijc_35087 crossref_primary_10_1016_j_beem_2024_101939 crossref_primary_10_1167_tvst_11_2_10 crossref_primary_10_1016_j_cancergen_2019_11_004 crossref_primary_10_2174_1566523220666200806111451 crossref_primary_10_3390_cancers13246174 crossref_primary_10_1016_j_brainresbull_2023_110860 crossref_primary_10_3389_fonc_2022_981230 crossref_primary_10_1038_s41388_021_02156_y crossref_primary_10_3390_medicina58121830 crossref_primary_10_1186_s12881_019_0770_6 crossref_primary_10_26442_18151434_2022_2_201431 crossref_primary_10_1016_j_ccell_2022_08_014 crossref_primary_10_18632_oncotarget_25805 crossref_primary_10_1016_j_beem_2024_101913 crossref_primary_10_1159_000530621 crossref_primary_10_1007_s12032_019_1250_8 crossref_primary_10_1158_0008_5472_CAN_20_0916 crossref_primary_10_1016_j_jid_2020_09_003 crossref_primary_10_1093_gigascience_giae113 crossref_primary_10_1002_ajmg_a_62071 crossref_primary_10_1093_ejendo_lvad051 crossref_primary_10_3390_cells9112365 crossref_primary_10_1158_2767_9764_CRC_23_0044 crossref_primary_10_3390_ijms23010352 crossref_primary_10_1016_j_jid_2020_12_017 crossref_primary_10_1158_1541_7786_MCR_18_1080 crossref_primary_10_6061_clinics_2021_e3222 crossref_primary_10_1016_j_prp_2022_153820 crossref_primary_10_1002_ijc_31871 crossref_primary_10_1056_NEJMcpc1904048 crossref_primary_10_1097_MD_0000000000010894 crossref_primary_10_1080_14737140_2021_1960160 crossref_primary_10_1016_j_jtho_2019_04_015 crossref_primary_10_3389_fimmu_2020_02062 crossref_primary_10_3390_ijms221910390 crossref_primary_10_7759_cureus_18456 crossref_primary_10_1024_1422_4917_a000803 crossref_primary_10_1016_j_phrs_2024_107544 crossref_primary_10_3390_jcm10081578 crossref_primary_10_1080_08880018_2022_2153951 crossref_primary_10_1002_1878_0261_70020 crossref_primary_10_1080_23723556_2020_1716618 crossref_primary_10_1186_s12885_024_13421_0 crossref_primary_10_1016_j_intimp_2024_113193 crossref_primary_10_1093_ejendo_lvae160 crossref_primary_10_1186_s12881_020_01137_4 crossref_primary_10_1007_s11912_018_0733_7 crossref_primary_10_1093_ejendo_lvae163 crossref_primary_10_1016_j_expneurol_2024_114914 crossref_primary_10_1186_s11689_024_09565_6 crossref_primary_10_1002_humu_23681 crossref_primary_10_1016_j_crmeth_2024_100772 crossref_primary_10_1038_s10038_022_01072_7 crossref_primary_10_1007_s12031_024_02271_x crossref_primary_10_1111_bjh_16006 crossref_primary_10_3389_fonc_2022_1052799 crossref_primary_10_1007_s40265_019_01113_0 crossref_primary_10_1242_jcs_238865 crossref_primary_10_1007_s00438_018_01529_5 crossref_primary_10_3390_ijms20030690 crossref_primary_10_3390_cancers16203513 crossref_primary_10_3390_genes12101543 crossref_primary_10_1097_DAD_0000000000001888 crossref_primary_10_3390_cancers16050994 crossref_primary_10_1016_j_gene_2023_147432 crossref_primary_10_1016_j_xjidi_2021_100044 crossref_primary_10_3390_ijms241310823 crossref_primary_10_1084_jem_20222056 crossref_primary_10_1158_2159_8290_CD_22_0786 crossref_primary_10_1016_j_cancergen_2021_03_004 crossref_primary_10_1186_s12859_021_04147_y crossref_primary_10_3390_cancers11111790 crossref_primary_10_1097_DAD_0000000000002387 crossref_primary_10_1200_PO_22_00421 crossref_primary_10_1093_genetics_iyab208 crossref_primary_10_1186_s13053_023_00262_4 crossref_primary_10_1158_1078_0432_CCR_18_3224 crossref_primary_10_1002_gcc_22758 crossref_primary_10_1097_MPA_0000000000001680 crossref_primary_10_1631_jzus_B2200116 crossref_primary_10_1002_ajmg_a_63346 crossref_primary_10_1007_s12672_024_00997_z crossref_primary_10_1038_s41591_018_0263_8 crossref_primary_10_3390_cancers14051321 crossref_primary_10_1200_PO_18_00028 crossref_primary_10_12998_wjcc_v10_i15_4761 crossref_primary_10_1016_j_jmb_2019_07_038 crossref_primary_10_1007_s00381_021_05436_w crossref_primary_10_3389_fgene_2022_917150 crossref_primary_10_1038_s41523_018_0089_z crossref_primary_10_1038_s41598_023_37266_y crossref_primary_10_3892_or_2021_8226 crossref_primary_10_2147_CMAR_S280174 crossref_primary_10_1016_j_celrep_2025_115365 crossref_primary_10_3389_fgene_2022_991314 crossref_primary_10_1016_j_pathol_2021_12_295 crossref_primary_10_18632_oncotarget_25989 crossref_primary_10_18632_oncotarget_27005 crossref_primary_10_3390_biomedicines10082044 crossref_primary_10_1136_jmedgenet_2018_105599 crossref_primary_10_1155_2018_6938130 crossref_primary_10_1200_PO_19_00136 crossref_primary_10_3389_fonc_2019_01221 crossref_primary_10_1038_s41467_018_07452_y crossref_primary_10_3389_fonc_2022_1086908 crossref_primary_10_1101_mcs_a003863 crossref_primary_10_1038_s41431_021_01015_4 crossref_primary_10_23868_202110007 crossref_primary_10_1016_j_jpedsurg_2024_161928 crossref_primary_10_1242_jcs_262343 crossref_primary_10_1200_PO_23_00168 crossref_primary_10_1038_s41523_025_00740_z crossref_primary_10_1007_s12185_019_02642_w crossref_primary_10_1016_j_jpi_2023_100196 crossref_primary_10_1126_sciadv_abc8145 crossref_primary_10_1080_10409238_2018_1431605 crossref_primary_10_1212_NXG_0000000000200003 crossref_primary_10_1073_pnas_2208960120 crossref_primary_10_1016_j_celrep_2020_107909 crossref_primary_10_1186_s13059_020_02164_3 crossref_primary_10_1186_s13000_024_01578_y crossref_primary_10_1080_13543784_2023_2263836 crossref_primary_10_1186_s40478_024_01875_z crossref_primary_10_1111_ejh_13702 crossref_primary_10_1007_s10014_020_00383_x crossref_primary_10_1159_000540707 crossref_primary_10_3390_cancers13081879 crossref_primary_10_1158_1535_7163_MCT_19_1017 crossref_primary_10_21294_1814_4861_2023_22_3_119_124 crossref_primary_10_4103_jotr_jotr_49_22 crossref_primary_10_1038_s42003_023_04815_0 crossref_primary_10_3390_cancers13246192 crossref_primary_10_1038_s41467_024_55251_5 crossref_primary_10_1007_s00401_019_02002_2 crossref_primary_10_3389_fendo_2025_1483305 crossref_primary_10_1177_10668969241311520 crossref_primary_10_1016_j_semcancer_2018_03_005 crossref_primary_10_1080_10428194_2024_2382329 crossref_primary_10_1007_s10014_017_0302_z crossref_primary_10_1200_PO_18_00343 crossref_primary_10_1016_j_mce_2017_09_024 crossref_primary_10_1038_s41416_018_0073_2 crossref_primary_10_3390_cancers12113326 crossref_primary_10_1007_s11060_020_03535_3 crossref_primary_10_3892_ijmm_2020_4614 crossref_primary_10_1007_s40257_019_00500_3 crossref_primary_10_1038_s41698_021_00145_8 crossref_primary_10_3389_fonc_2024_1323313 crossref_primary_10_1080_14728222_2018_1465931 crossref_primary_10_3390_cells6040045 crossref_primary_10_1158_0008_5472_CAN_19_3984 crossref_primary_10_1111_pin_12979 crossref_primary_10_3390_cancers14092315 crossref_primary_10_1016_j_tranon_2019_10_016 crossref_primary_10_1021_acs_jpcb_4c00873 crossref_primary_10_1016_j_rpor_2020_04_010 crossref_primary_10_1080_17474086_2020_1685866 crossref_primary_10_1016_j_annonc_2020_03_291 crossref_primary_10_1210_clinem_dgae241 crossref_primary_10_1002_mc_23165 crossref_primary_10_1016_j_jdcr_2024_09_022 crossref_primary_10_3390_genes12050781 crossref_primary_10_18231_j_ijpo_2022_060 crossref_primary_10_1007_s00428_023_03663_x crossref_primary_10_3390_cancers12040927 crossref_primary_10_3390_cancers16193266 crossref_primary_10_3389_fsurg_2022_842054 crossref_primary_10_1038_s41467_024_48616_3 crossref_primary_10_1093_jscr_rjaa039 crossref_primary_10_1158_1541_7786_MCR_19_1201 crossref_primary_10_1136_jclinpath_2019_206208 crossref_primary_10_1038_s43856_025_00767_0 crossref_primary_10_18705_2782_3806_2022_2_4_91_96 |
| Cites_doi | 10.1371/journal.pcbi.1004731 10.1038/nature13385 10.1038/ng1936 10.1002/path.4230 10.1038/ng.3400 10.1056/NEJM199411243312102 10.1038/ncomms5852 10.1016/j.cancergen.2011.03.001 10.1038/nature12213 10.1146/annurev-neuro-060909-153215 10.1038/nature12634 10.1002/gcc.20289 10.1016/j.cancergen.2011.10.004 10.1182/blood-2009-02-205146 10.1371/journal.pone.0047717 10.1038/nature09208 10.1158/2159-8290.CD-12-0313 10.1038/ejhg.2011.113 10.1016/j.ebiom.2016.04.005 10.1038/ncomms4156 10.1038/sj.bjc.6603227 10.1158/2159-8290.CD-12-0095 10.1016/j.beem.2010.05.001 10.1016/j.ccr.2005.07.004 10.1159/000126545 10.1111/cen.12071 10.1002/humu.22162 10.1016/j.sbi.2015.01.004 10.1136/jclinpath-2014-202447 10.1038/ng.3564 10.1038/ncomms11479 10.1038/ng.3420 10.1056/NEJM199706123362404 10.1016/S0020-7292(06)60033-7 10.1002/humu.21418 10.1038/modpathol.2013.135 10.1136/jmg.2009.075937 10.1182/blood-2007-06-095075 10.1038/leu.2011.296 10.1038/sj.onc.1209264 10.1073/pnas.1404341111 10.1093/hmg/dds374 10.1038/ng.3361 10.1111/j.1749-6632.1986.tb48062.x 10.1158/1078-0432.CCR-07-1005 10.1016/S0022-5347(05)68171-2 10.1002/humu.20601 10.1086/510781 10.1002/ajh.23403 10.1016/j.cell.2013.09.034 10.1016/j.celrep.2016.10.009 10.1016/S1470-2045(15)00077-7 10.1001/archderm.141.1.71 10.1158/1078-0432.CCR-13-0398 10.1016/S0304-3835(01)00648-6 10.1016/j.hoc.2012.07.006 10.1002/humu.21271 10.1038/nrc3911 10.1002/ajmg.a.35550 10.1038/nature11412 10.1038/ng.2359 10.1074/jbc.271.27.16409 10.1136/jmg.2007.049346 10.1016/S0092-8674(01)00245-8 10.1016/j.canlet.2013.06.014 10.1002/1097-0142(19931101)72:9<2746::AID-CNCR2820720936>3.0.CO;2-W 10.1038/nature12965 10.1038/ng.2405 10.1038/ng0293-118 10.1038/ng.3095 10.1038/sj.onc.1202829 10.1158/2159-8290.CD-12-0470 10.1038/nature11252 10.1016/j.cell.2012.06.024 10.1016/j.cell.2006.01.016 10.1182/blood.V94.1.225.413k24_225_232 10.1073/pnas.1213968110 10.1159/000126561 10.1038/nature07423 10.1038/nature12912 10.1038/nrc1299 10.1038/ng.2396 10.1016/S0002-9440(10)65322-9 10.1523/JNEUROSCI.3242-12.2012 10.1093/hmg/dds402 10.1073/pnas.1018872108 10.1158/1078-0432.CCR-09-2639 10.1007/s10048-012-0332-y 10.1038/ncomms11908 10.1530/ERC-13-0046 10.1158/2159-8290.CD-13-0146 10.1073/pnas.68.4.820 10.1016/j.ygyno.2013.06.019 10.1593/neo.08784 10.1038/nature07943 10.1111/cge.12187 10.1002/ajmg.a.33386 10.1001/jama.2009.1663 10.1007/s00439-017-1779-6 10.1038/ng0193-62 10.1146/annurev-pathol-011110-130235 10.1146/annurev.pathol.1.110304.100043 10.1038/nature10868 10.1038/ncomms4887 10.3322/caac.20107 10.1158/2159-8290.CD-13-0741 10.1371/journal.pone.0011408 10.1038/nature09784 10.1038/nature11017 10.1038/nrc.2015.10 10.1593/neo.08312 10.1517/17530059.2010.494660 10.1016/j.cancergen.2012.01.009 10.1002/humu.20826 10.1038/ncomms6893 10.1177/1947601912443127 10.1146/annurev-genom-091212-153429 10.1007/978-3-642-32864-0_20 10.1073/pnas.1010978107 10.1038/leu.2012.288 10.1073/pnas.0503224102 10.1038/nature13561 10.1126/science.1133427 10.1038/bjc.1994.404 10.1007/s10689-006-9001-3 10.18632/oncotarget.16542 10.1038/nature11282 10.1038/bjc.1995.206 10.1086/374821 10.1016/0092-8674(90)90252-A 10.1001/archopht.121.9.1311 10.1016/j.cell.2012.08.029 10.1056/NEJMoa1502583 10.1038/onc.2010.245 10.1038/ng.2682 10.1371/journal.pone.0038463 10.1158/1535-7163.MCT-13-0482 10.1038/nature10166 10.1136/jmg.26.11.704 10.2741/3727 10.1073/pnas.90.23.10914 10.1158/0008-5472.CAN-13-2625 10.1002/pbc.10381 10.1016/j.ccr.2004.09.022 10.1016/S1470-2045(09)70033-6 10.1038/nm.2673 10.1016/j.cell.2010.06.004 10.1016/j.ccr.2009.12.020 10.1097/PAS.0000000000000451 10.1126/science.aai8690 10.1007/978-3-642-32864-0_10 10.1677/erc.1.00776 10.1016/S0022-2836(03)00514-X 10.1093/hmg/ddw191 10.1007/s11912-016-0526-9 10.1016/j.febslet.2012.06.006 10.1126/science.1164382 10.1126/science.1235122 10.1038/nature07385 10.1146/annurev.pathol.2.010506.091940 10.1534/genetics.112.142802 10.1038/nature11404 10.1111/exd.13212 10.1002/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N 10.1158/1078-0432.CCR-15-2377 10.1007/s005950300074 |
| ContentType | Journal Article |
| Copyright | Copyright BioMed Central 2017 The Author(s). 2017 |
| Copyright_xml | – notice: Copyright BioMed Central 2017 – notice: The Author(s). 2017 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 8AO 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s40246-017-0109-3 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1479-7364 |
| EndPage | 19 |
| ExternalDocumentID | oai_doaj_org_article_af2a8b2e15014b06bbcd138fb2908481 PMC5480124 28637487 10_1186_s40246_017_0109_3 |
| Genre | Journal Article Review |
| GroupedDBID | --- 0R~ 2JY 36B 4.4 53G 5GY 5VS 7X7 88E 8AO 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABUWG ACGFS ACPRK ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION DIK EBLON EBS EJD EMB EMOBN F5P FYUFA GROUPED_DOAJ H13 HCIFZ HMCUK HYE IAO IHR IHW INH ISR ITC KQ8 LK8 M1P M48 M7P OK1 PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SJN SOJ SV3 UKHRP -A0 3V. 88A ACRMQ ADINQ C24 CGR CUY CVF ECM EIF M0L M~E NPM 7XB 8FK AHSBF AZQEC DWQXO GNUQQ K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c660t-c99c90b98283918c04949e2dc6e925ae2d28f507e633d6720bbf726c857fa4ac3 |
| IEDL.DBID | M48 |
| ISSN | 1479-7364 1473-9542 |
| IngestDate | Wed Aug 27 01:18:42 EDT 2025 Thu Aug 21 17:13:49 EDT 2025 Fri Jul 11 07:27:17 EDT 2025 Fri Jul 25 19:57:28 EDT 2025 Wed Feb 19 02:41:18 EST 2025 Thu Apr 24 23:11:15 EDT 2025 Tue Jul 01 03:47:45 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Somatic mutations Phaeochromocytoma Glioblastoma Melanoma NF1 Breast cancer Sporadic tumours Lung cancers Cancer Leukaemia |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c660t-c99c90b98283918c04949e2dc6e925ae2d28f507e633d6720bbf726c857fa4ac3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s40246-017-0109-3 |
| PMID | 28637487 |
| PQID | 1915663366 |
| PQPubID | 27863 |
| PageCount | 19 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_af2a8b2e15014b06bbcd138fb2908481 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5480124 proquest_miscellaneous_1912612652 proquest_journals_1915663366 pubmed_primary_28637487 crossref_primary_10_1186_s40246_017_0109_3 crossref_citationtrail_10_1186_s40246_017_0109_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-06-21 |
| PublicationDateYYYYMMDD | 2017-06-21 |
| PublicationDate_xml | – month: 06 year: 2017 text: 2017-06-21 day: 21 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Human genomics |
| PublicationTitleAlternate | Hum Genomics |
| PublicationYear | 2017 |
| Publisher | BioMed Central BMC |
| Publisher_xml | – name: BioMed Central – name: BMC |
| References | M Upadhyaya (109_CR38) 2010; 4 M Peifer (109_CR77) 2012; 44 M Upadhyaya (109_CR5) 2007; 80 Cancer Genome Atlas N (109_CR143) 2012; 487 SD Colman (109_CR32) 1996; 58 M Giannakis (109_CR144) 2016; 17 I Matsui (109_CR152) 1993; 72 PA Futreal (109_CR160) 2004; 4 W Lee (109_CR96) 2014; 46 DN Cooper (109_CR2) 2012 BS Braun (109_CR81) 2008; 14 A Bashashati (109_CR178) 2013; 231 MM Walther (109_CR120) 1999; 162 N Sangha (109_CR113) 2008; 10 S Wullschleger (109_CR153) 2006; 124 DW Parsons (109_CR132) 2008; 321 AG Knudson (109_CR151) 1993; 90 DT Jones (109_CR135) 2013; 45 109_CR14 MJ Garnett (109_CR57) 2004; 6 EC Bruin de (109_CR71) 2014; 4 J Welander (109_CR123) 2013; 20 E Bennett (109_CR1) 2009; 7 M Wu (109_CR139) 2006; 25 M Holzel (109_CR130) 2010; 142 S Seshagiri (109_CR145) 2012; 488 B Vogelstein (109_CR147) 2013; 339 V Aaltonen (109_CR148) 1999; 154 D Lipson (109_CR70) 2012; 18 Cancer Genome Atlas Research N (109_CR170) 2011; 474 A Ring (109_CR112) 2004; 11 K Furukawa (109_CR166) 2003; 33 JL Bader (109_CR150) 1986; 486 R Akbani (109_CR54) 2015; 6 LB Andersen (109_CR48) 1993; 3 M Imielinski (109_CR66) 2012; 150 JS Ross (109_CR78) 2014; 67 D Viskochil (109_CR11) 1990; 62 BA Cutts (109_CR92) 2009; 114 D Han (109_CR131) 2011; 2 N Ratner (109_CR47) 2015; 15 L Garcia-Orti (109_CR83) 2012; 7 H Ogata (109_CR103) 2001; 172 J Gao (109_CR46) 2013; 6 C Kandoth (109_CR177) 2013; 502 B Pereira (109_CR109) 2016; 7 C Haferlach (109_CR84) 2012; 26 CD McFarland (109_CR158) 2014; 111 M Lammert (109_CR4) 2005; 141 L Mittempergher (109_CR117) 2016; 18 CM Rudin (109_CR76) 2012; 44 SL Cooke (109_CR116) 2010; 29 MH Nissan (109_CR52) 2014; 74 B Pereira (109_CR108) 2016; 7 109_CR115 MS Lawrence (109_CR162) 2014; 505 MR Ahmadian (109_CR174) 1996; 271 R Nussinov (109_CR159) 2015; 32 L Chen (109_CR154) 2017; 355 K Scheffzek (109_CR15) 2012; 586 T Wiesner (109_CR60) 2015; 39 Cancer Genome Atlas Research N (109_CR72) 2012; 489 S Devarakonda (109_CR75) 2015; 16 DG Evans (109_CR28) 2016; 7 AI McClatchey (109_CR13) 2007; 2 WE Tidyman (109_CR39) 2016; 25 I Bozic (109_CR155) 2010; 107 N Burnichon (109_CR124) 2012; 21 AP Heintz (109_CR114) 2006; 95 Suppl 1 JS Ross (109_CR180) 2013; 130 M Krauthammer (109_CR49) 2015; 47 T Shojaei-Brosseau (109_CR128) 2004; 42 E Pros (109_CR30) 2008; 29 Z Kalender Atak (109_CR88) 2012; 7 C Lazaro (109_CR33) 1994; 331 MR Ahmadian (109_CR173) 2003; 329 A Jemal (109_CR69) 2011; 61 R Minkelen van (109_CR26) 2014; 85 T Sjoblom (109_CR101) 2006; 314 H Kehrer-Sawatzki (109_CR37) 2012; 13 AE Murthy (109_CR129) 1993; 3 VJ Mar (109_CR59) 2013; 19 O Abdel-Wahab (109_CR94) 2013; 27 AM Mendes-Pereira (109_CR111) 2012; 109 CW Brennan (109_CR134) 2013; 155 K Scheffzek (109_CR16) 2012 CA Koch (109_CR119) 2001; 35 CM Johannessen (109_CR17) 2005; 102 SR Whittaker (109_CR53) 2013; 3 JD Campbell (109_CR74) 2016; 48 VK Hill (109_CR56) 2013; 14 E Boudry-Labis (109_CR82) 2013; 88 DG Evans (109_CR99) 2011; 19 109_CR64 109_CR63 BV Balgobind (109_CR79) 2008; 111 N Shima (109_CR104) 2007; 39 S Misawa (109_CR86) 1997; 11 Cancer Genome Atlas Research N (109_CR67) 2014; 511 ER Fearon (109_CR146) 2011; 6 E Stieglitz (109_CR97) 2015; 47 J Welander (109_CR121) 2012; 21 Cancer Genome Atlas Research N (109_CR171) 2008; 455 Y Zhu (109_CR137) 2005; 8 S Seton-Rogers (109_CR164) 2016; 16 R Margueron (109_CR91) 2011; 469 CD McFarland (109_CR157) 2013; 110 K Kulkarni-Datar (109_CR118) 2013; 339 L Cawkwell (109_CR141) 1994; 70 AG Knudson Jr (109_CR10) 1971; 68 K Cichowski (109_CR12) 2001; 104 E Cerami (109_CR45) 2012; 2 E Pasmant (109_CR169) 2010; 31 S Sharif (109_CR98) 2007; 44 I Bottillo (109_CR31) 2010; 152A L Messiaen (109_CR34) 2011; 32 E Hodis (109_CR51) 2012; 150 SR Galan (109_CR126) 2013; 78 JS Ross (109_CR149) 2014; 27 A Prahallad (109_CR165) 2012; 483 T Raedt De (109_CR168) 2003; 72 H Brems (109_CR9) 2009; 10 109_CR7 L Walker (109_CR8) 2006; 95 KA Kolquist (109_CR87) 2011; 204 DH Gutmann (109_CR138) 1999; 18 H Ding (109_CR175) 2003; 63 109_CR43 A Caye (109_CR90) 2015; 47 109_CR42 109_CR41 109_CR44 F Meric-Bernstam (109_CR107) 2014; 13 T Raedt De (109_CR95) 2014; 514 L Thomas (109_CR36) 2012; 33 R Akbani (109_CR55) 2014; 5 G Opocher (109_CR122) 2010; 24 PD Stenson (109_CR27) 2017 O Abdel-Wahab (109_CR93) 2012; 26 K Wimmer (109_CR35) 2006; 45 LM Messiaen (109_CR24) 2000; 15 C Shilyansky (109_CR18) 2010; 33 KL Kanchi (109_CR179) 2014; 5 PJ Stephens (109_CR102) 2012; 486 PE Hollstein (109_CR19) 2013; 3 AJ Redig (109_CR68) 2016; 22 M Krauthammer (109_CR50) 2012; 44 DH Gutmann (109_CR21) 2012; 32 B Parkin (109_CR85) 2010; 16 SM Huson (109_CR3) 1989; 26 S Griffiths (109_CR23) 2007; 6 XY Cui (109_CR110) 2008; 28 RJ Deyell (109_CR127) 2011; 204 DN Louis (109_CR133) 2006; 1 RG Verhaak (109_CR136) 2010; 17 109_CR163 M Upadhyaya (109_CR6) 2011; 16 109_CR161 SA Madanikia (109_CR100) 2012; 158A Cancer Genome Atlas N (109_CR106) 2012; 490 L Fishbein (109_CR125) 2012; 205 Z Kan (109_CR176) 2010; 466 I Bozic (109_CR156) 2016; 12 T Ahlquist (109_CR140) 2008; 10 L Messiaen (109_CR172) 2009; 302 WJ Foster (109_CR62) 2003; 121 L Side (109_CR89) 1997; 336 MD Wallace (109_CR105) 2012; 192 B Leggett (109_CR142) 1995; 71 MR Stratton (109_CR40) 2009; 458 109_CR20 AH Shain (109_CR61) 2015; 373 L Ding (109_CR65) 2008; 455 109_CR25 SM Dhanasekaran (109_CR73) 2014; 5 T Fioretos (109_CR80) 1999; 94 Cancer Genome Atlas Research N (109_CR167) 2014; 507 109_CR22 O Maertens (109_CR58) 2013; 3 VF Mautner (109_CR29) 2010; 47 21280148 - Hum Mutat. 2011 Feb;32(2):213-9 7734302 - Br J Cancer. 1995 May;71(5):1070-3 26861459 - Clin Cancer Res. 2016 Jul 1;22(13):3148-56 22015770 - Leukemia. 2012 Apr;26(4):834-9 7947085 - Br J Cancer. 1994 Nov;70(5):813-8 22728242 - FEBS Lett. 2012 Aug 14;586(17):2662-73 24535670 - Cancer Discov. 2014 May;4(5):606-19 27241520 - Curr Oncol Rep. 2016 Jul;18(7):44 22851646 - Genetics. 2012 Oct;192(2):385-96 20543202 - J Med Genet. 2010 Sep;47(9):623-30 24576830 - Cancer Res. 2014 Apr 15;74(8):2340-50 24608573 - Mol Cancer Ther. 2014 May;13(5):1382-9 23496147 - Expert Opin Med Diagn. 2010 Jul;4(4):307-22 25277973 - Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15138-43 22200086 - Cancer Genet. 2011 Nov;204(11):603-28 21504710 - Cancer Genet. 2011 Mar;204(3):113-21 20505189 - Clin Cancer Res. 2010 Aug 15;16(16):4135-47 18172006 - Blood. 2008 Apr 15;111(8):4322-8 18948947 - Nature. 2008 Oct 23;455(7216):1069-75 12963615 - Arch Ophthalmol. 2003 Sep;121(9):1311-5 26559571 - N Engl J Med. 2015 Nov 12;373(20):1926-36 24476821 - Nature. 2014 Mar 20;507(7492):315-22 8402499 - Cancer. 1993 Nov 1;72(9):2746-54 27412009 - Hum Mol Genet. 2016 Oct 1;25(R2):R123-R132 18971180 - Nan Fang Yi Ke Da Xue Xue Bao. 2008 Oct;28(10):1813-5 21090969 - Annu Rev Pathol. 2011;6:479-507 17369502 - J Med Genet. 2007 Aug;44(8):481-4 15937108 - Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8 19048115 - Neoplasia. 2008 Dec;10(12):1362-72, following 1372 10524872 - J Urol. 1999 Nov;162(5):1582-6 10079253 - Am J Pathol. 1999 Mar;154(3):755-65 2511318 - J Med Genet. 1989 Nov;26(11):704-11 19360079 - Nature. 2009 Apr 9;458(7239):719-24 24871328 - Nat Commun. 2014 May 29;5:3887 1694727 - Cell. 1990 Jul 13;62(1):187-92 10381517 - Blood. 1999 Jul 1;94(1):225-32 27264733 - Nat Commun. 2016 Jun 06;7:11908 23770567 - Nature. 2013 Jul 11;499(7457):214-8 18413813 - Clin Cancer Res. 2008 Apr 15;14(8):2249-52 22962301 - Hum Mol Genet. 2012 Dec 15;21(26):5397-405 23756430 - Endocr Relat Cancer. 2013 Jul 04;20(4):C13-7 21196210 - Front Biosci (Landmark Ed). 2011 Jan 01;16:937-51 25877329 - Nat Rev Cancer. 2015 May;15(5):290-301 27322474 - EBioMedicine. 2016 May;7:212-20 25079552 - Nature. 2014 Jul 31;511(7511):543-50 23171796 - Cancer Discov. 2013 Mar;3(3):338-49 16959974 - Science. 2006 Oct 13;314(5797):268-74 15613444 - Endocr Relat Cancer. 2004 Dec;11(4):643-58 20668451 - Nature. 2010 Aug 12;466(7308):869-73 21694737 - Eur J Hum Genet. 2011 Nov;19(11):1187-91 3105405 - Ann N Y Acad Sci. 1986;486:57-65 23791828 - Gynecol Oncol. 2013 Sep;130(3):554-9 22941189 - Nat Genet. 2012 Oct;44(10):1111-6 12660952 - Am J Hum Genet. 2003 May;72(5):1288-92 27158780 - Nat Genet. 2016 Jun;48(6):607-16 8663212 - J Biol Chem. 1996 Jul 5;271(27):16409-15 23875803 - Annu Rev Genomics Hum Genet. 2013;14:257-79 23010473 - Hum Mol Genet. 2012 Dec 15;21(26):5406-16 14993899 - Nat Rev Cancer. 2004 Mar;4(3):177-83 23539594 - Science. 2013 Mar 29;339(6127):1546-58 23288408 - Cancer Discov. 2013 Mar;3(3):350-62 22281684 - Nature. 2012 Jan 26;483(7387):100-3 20345245 - Annu Rev Neurosci. 2010;33:221-43 18772396 - Science. 2008 Sep 26;321(5897):1807-12 24132290 - Nature. 2013 Oct 17;502(7471):333-9 15655144 - Arch Dermatol. 2005 Jan;141(1):71-4 9209448 - Leukemia. 1997 Apr;11 Suppl 3:533-5 20581869 - Oncogene. 2010 Sep 2;29(35):4905-13 20129251 - Cancer Cell. 2010 Jan 19;17(1):98-110 16944272 - Fam Cancer. 2007;6(1):21-34 20513137 - Hum Mutat. 2010 Jun;31(6):E1506-18 26149886 - Lancet Oncol. 2015 Jul;16(7):e342-51 22810696 - Nature. 2012 Jul 18;487(7407):330-7 16469695 - Cell. 2006 Feb 10;124(3):471-84 22817889 - Cell. 2012 Jul 20;150(2):251-63 22842228 - Nat Genet. 2012 Sep;44(9):1006-14 28349240 - Hum Genet. 2017 Jun;136(6):665-677 25629879 - Nat Commun. 2015 Jan 28;6:4852 23000897 - Nature. 2012 Oct 4;490(7418):61-70 26667852 - Nat Rev Cancer. 2016 Jan;16(1):5 17160901 - Am J Hum Genet. 2007 Jan;80(1):140-51 12734724 - Surg Today. 2003;33(5):323-7 9180088 - N Engl J Med. 1997 Jun 12;336(24):1713-20 23817572 - Nat Genet. 2013 Aug;45(8):927-32 12787671 - J Mol Biol. 2003 Jun 13;329(4):699-710 20503322 - Am J Med Genet A. 2010 Jun;152A(6):1467-73 27622733 - Exp Dermatol. 2016 Sep 13;:null 25240281 - Nat Genet. 2014 Nov;46(11):1227-32 21248841 - Nature. 2011 Jan 20;469(7330):343-9 23055477 - J Neurosci. 2012 Oct 10;32(41):14087-93 26457648 - Nat Genet. 2015 Nov;47(11):1334-40 7969279 - N Engl J Med. 1994 Nov 24;331(21):1403-7 10862084 - Hum Mutat. 2000;15(6):541-55 23165953 - Am J Med Genet A. 2012 Dec;158A(12 ):3056-60 23661552 - Cancer Discov. 2013 Aug;3(8):880-93 14752801 - Pediatr Blood Cancer. 2004 Jan;42(1):99-105 16786042 - Br J Cancer. 2006 Jul 17;95(2):233-8 25531467 - Nat Commun. 2014 Dec 22;5:5893 26828429 - PLoS Comput Biol. 2016 Feb 01;12(2):e1004731 23833303 - Clin Cancer Res. 2013 Sep 1;19(17):4589-98 21482774 - Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2730-5 24120142 - Cell. 2013 Oct 10;155(2):462-77 24978188 - J Clin Pathol. 2014 Sep;67(9):772-6 8490657 - Nat Genet. 1993 Jan;3(1):62-6 26076063 - Am J Surg Pathol. 2015 Oct;39(10 ):1357-62 20655465 - Cell. 2010 Jul 23;142(2):218-29 24390350 - Nature. 2014 Jan 23;505(7484):495-501 28209900 - Science. 2017 Feb 17;355(6326):752-756 22960745 - Nature. 2012 Sep 27;489(7417):519-25 28380455 - Oncotarget. 2017 Jun 20;8(25):40683-40692 18039098 - Annu Rev Pathol. 2007;2:191-216 23388632 - Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2910-5 23550210 - Sci Signal. 2013 Apr 02;6(269):pl1 17161157 - Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 18546366 - Hum Mutat. 2008 Sep;29(9):E173-93 11308996 - Endocr Regul. 2001 Mar;35(1):43-52 22941188 - Nat Genet. 2012 Oct;44(10 ):1104-10 23147254 - Leukemia. 2013 Jan;27(1):10-5 22429592 - Cancer Genet. 2012 Jan-Feb;205(1-2):1-11 23791886 - Cancer Lett. 2013 Oct 10;339(2):237-46 23460398 - Am J Hematol. 2013 Apr;88(4):306-11 23780408 - J Pathol. 2013 Sep;231(1):21-34 7902574 - Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10914-21 24448499 - Nat Commun. 2014;5:3156 12615729 - Cancer Res. 2003 Mar 1;63(5):1106-13 25661093 - Curr Opin Struct Biol. 2015 Jun;32:25-32 23077663 - PLoS One. 2012;7(10):e47717 11239415 - Cell. 2001 Feb 23;104(4):593-604 22807134 - Hum Mutat. 2012 Dec;33(12):1687-96 11566491 - Cancer Lett. 2001 Oct 30;172(2):159-64 21296855 - CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 18592002 - Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 21115163 - Best Pract Res Clin Endocrinol Metab. 2010 Dec;24(6):943-56 8499944 - Nat Genet. 1993 Feb;3(2):118-21 23009937 - Hematol Oncol Clin North Am. 2012 Oct;26(5):1053-64 10442636 - Oncogene. 1999 Aug 5;18(31):4450-9 22980975 - Cell. 2012 Sep 14;150(6):1107-20 22581253 - Neurogenetics. 2012 Aug;13(3):229-36 16288202 - Oncogene. 2006 Apr 13;25(16):2297-303 19710506 - Blood. 2009 Oct 22;114(17):3629-32 23656349 - Clin Genet. 2014 Apr;85(4):318-27 19410195 - Lancet Oncol. 2009 May;10(5):508-15 22588877 - Cancer Discov. 2012 May;2(5):401-4 8644707 - Am J Hum Genet. 1996 Mar;58(3):484-90 22675565 - PLoS One. 2012;7(6):e38463 27161491 - Nat Commun. 2016 May 10;7:11479 22327622 - Nat Med. 2012 Feb 12;18(3):382-4 18039109 - Annu Rev Pathol. 2006;1:97-117 16283621 - Genes Chromosomes Cancer. 2006 Mar;45(3):265-76 18772890 - Nature. 2008 Oct 23;455(7216):1061-8 23061808 - Clin Endocrinol (Oxf). 2013 Feb;78(2):165-75 21720365 - Nature. 2011 Jun 29;474(7353):609-15 17143284 - Nat Genet. 2007 Jan;39(1):93-8 25119042 - Nature. 2014 Oct 9;514(7521):247-51 17960768 - Hum Mutat. 2008 Jan;29(1):74-82 26457647 - Nat Genet. 2015 Nov;47(11):1326-33 23887298 - Mod Pathol. 2014 Feb;27(2):271-80 22737269 - Genes Cancer. 2011 Nov;2(11):1034-43 20876136 - Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18545-50 22722201 - Nature. 2012 May 16;486(7403):400-4 26214590 - Nat Genet. 2015 Sep;47(9):996-1002 5279523 - Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 20844748 - PLoS One. 2010 Sep 10;5(9):null 19920235 - JAMA. 2009 Nov 18;302(19):2111-8 27760322 - Cell Rep. 2016 Oct 18;17 (4):1206 15488754 - Cancer Cell. 2004 Oct;6(4):313-9 16098465 - Cancer Cell. 2005 Aug;8(2):119-30 22895193 - Nature. 2012 Aug 30;488(7413):660-4 |
| References_xml | – volume: 12 start-page: e1004731 issue: 2 year: 2016 ident: 109_CR156 publication-title: PLoS Comput Biol doi: 10.1371/journal.pcbi.1004731 – volume: 511 start-page: 543 issue: 7511 year: 2014 ident: 109_CR67 publication-title: Nature doi: 10.1038/nature13385 – volume: 39 start-page: 93 issue: 1 year: 2007 ident: 109_CR104 publication-title: Nat Genet doi: 10.1038/ng1936 – volume: 231 start-page: 21 issue: 1 year: 2013 ident: 109_CR178 publication-title: J Pathol doi: 10.1002/path.4230 – volume: 47 start-page: 1326 issue: 11 year: 2015 ident: 109_CR97 publication-title: Nat Genet doi: 10.1038/ng.3400 – volume: 331 start-page: 1403 issue: 21 year: 1994 ident: 109_CR33 publication-title: N Engl J Med doi: 10.1056/NEJM199411243312102 – volume: 6 start-page: 4852 year: 2015 ident: 109_CR54 publication-title: Nat Commun doi: 10.1038/ncomms5852 – volume: 204 start-page: 113 issue: 3 year: 2011 ident: 109_CR127 publication-title: Cancer Genet doi: 10.1016/j.cancergen.2011.03.001 – ident: 109_CR163 doi: 10.1038/nature12213 – volume: 33 start-page: 221 year: 2010 ident: 109_CR18 publication-title: Annu Rev Neurosci doi: 10.1146/annurev-neuro-060909-153215 – volume: 502 start-page: 333 issue: 7471 year: 2013 ident: 109_CR177 publication-title: Nature doi: 10.1038/nature12634 – volume: 45 start-page: 265 issue: 3 year: 2006 ident: 109_CR35 publication-title: Genes Chromosomes Cancer doi: 10.1002/gcc.20289 – volume: 204 start-page: 603 issue: 11 year: 2011 ident: 109_CR87 publication-title: Cancer Genet doi: 10.1016/j.cancergen.2011.10.004 – volume: 114 start-page: 3629 issue: 17 year: 2009 ident: 109_CR92 publication-title: Blood doi: 10.1182/blood-2009-02-205146 – volume: 7 start-page: e47717 issue: 10 year: 2012 ident: 109_CR83 publication-title: PLoS One doi: 10.1371/journal.pone.0047717 – volume: 466 start-page: 869 issue: 7308 year: 2010 ident: 109_CR176 publication-title: Nature doi: 10.1038/nature09208 – volume: 3 start-page: 338 issue: 3 year: 2013 ident: 109_CR58 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-12-0313 – volume: 19 start-page: 1187 issue: 11 year: 2011 ident: 109_CR99 publication-title: Eur J Hum Genet doi: 10.1038/ejhg.2011.113 – volume: 7 start-page: 212 year: 2016 ident: 109_CR28 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2016.04.005 – volume: 5 start-page: 3156 year: 2014 ident: 109_CR179 publication-title: Nat Commun doi: 10.1038/ncomms4156 – volume: 95 start-page: 233 issue: 2 year: 2006 ident: 109_CR8 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603227 – volume: 2 start-page: 401 issue: 5 year: 2012 ident: 109_CR45 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-12-0095 – volume: 24 start-page: 943 issue: 6 year: 2010 ident: 109_CR122 publication-title: Best Pract Res Clin Endocrinol Metab doi: 10.1016/j.beem.2010.05.001 – volume: 8 start-page: 119 issue: 2 year: 2005 ident: 109_CR137 publication-title: Cancer Cell doi: 10.1016/j.ccr.2005.07.004 – ident: 109_CR25 doi: 10.1159/000126545 – volume: 78 start-page: 165 issue: 2 year: 2013 ident: 109_CR126 publication-title: Clin Endocrinol (Oxf) doi: 10.1111/cen.12071 – volume: 33 start-page: 1687 issue: 12 year: 2012 ident: 109_CR36 publication-title: Hum Mutat doi: 10.1002/humu.22162 – volume: 32 start-page: 25 year: 2015 ident: 109_CR159 publication-title: Curr Opin Struct Biol doi: 10.1016/j.sbi.2015.01.004 – volume: 67 start-page: 772 issue: 9 year: 2014 ident: 109_CR78 publication-title: J Clin Pathol doi: 10.1136/jclinpath-2014-202447 – volume: 48 start-page: 607 issue: 6 year: 2016 ident: 109_CR74 publication-title: Nat Genet doi: 10.1038/ng.3564 – volume: 7 start-page: 11479 year: 2016 ident: 109_CR109 publication-title: Nat Commun doi: 10.1038/ncomms11479 – volume: 47 start-page: 1334 issue: 11 year: 2015 ident: 109_CR90 publication-title: Nat Genet doi: 10.1038/ng.3420 – volume: 336 start-page: 1713 issue: 24 year: 1997 ident: 109_CR89 publication-title: N Engl J Med doi: 10.1056/NEJM199706123362404 – volume: 95 Suppl 1 start-page: S161 year: 2006 ident: 109_CR114 publication-title: Int J Gynaecol Obstet doi: 10.1016/S0020-7292(06)60033-7 – ident: 109_CR44 – volume: 32 start-page: 213 issue: 2 year: 2011 ident: 109_CR34 publication-title: Hum Mutat doi: 10.1002/humu.21418 – volume: 11 start-page: 533 issue: Suppl 3 year: 1997 ident: 109_CR86 publication-title: Leukemia – volume: 27 start-page: 271 issue: 2 year: 2014 ident: 109_CR149 publication-title: Mod Pathol doi: 10.1038/modpathol.2013.135 – volume: 47 start-page: 623 issue: 9 year: 2010 ident: 109_CR29 publication-title: J Med Genet doi: 10.1136/jmg.2009.075937 – volume: 111 start-page: 4322 issue: 8 year: 2008 ident: 109_CR79 publication-title: Blood doi: 10.1182/blood-2007-06-095075 – volume: 26 start-page: 834 issue: 4 year: 2012 ident: 109_CR84 publication-title: Leukemia doi: 10.1038/leu.2011.296 – volume: 25 start-page: 2297 issue: 16 year: 2006 ident: 109_CR139 publication-title: Oncogene doi: 10.1038/sj.onc.1209264 – volume: 111 start-page: 15138 issue: 42 year: 2014 ident: 109_CR158 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1404341111 – volume: 21 start-page: 5397 issue: 26 year: 2012 ident: 109_CR124 publication-title: Hum Mol Genet doi: 10.1093/hmg/dds374 – volume: 47 start-page: 996 issue: 9 year: 2015 ident: 109_CR49 publication-title: Nat Genet doi: 10.1038/ng.3361 – volume: 486 start-page: 57 year: 1986 ident: 109_CR150 publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.1986.tb48062.x – volume: 14 start-page: 2249 issue: 8 year: 2008 ident: 109_CR81 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-1005 – volume: 162 start-page: 1582 issue: 5 year: 1999 ident: 109_CR120 publication-title: J Urol doi: 10.1016/S0022-5347(05)68171-2 – ident: 109_CR7 doi: 10.1002/humu.20601 – volume: 80 start-page: 140 issue: 1 year: 2007 ident: 109_CR5 publication-title: Am J Hum Genet doi: 10.1086/510781 – volume: 88 start-page: 306 issue: 4 year: 2013 ident: 109_CR82 publication-title: Am J Hematol doi: 10.1002/ajh.23403 – volume: 155 start-page: 462 issue: 2 year: 2013 ident: 109_CR134 publication-title: Cell doi: 10.1016/j.cell.2013.09.034 – volume: 17 start-page: 1206 issue: 4 year: 2016 ident: 109_CR144 publication-title: Cell Rep doi: 10.1016/j.celrep.2016.10.009 – volume: 16 start-page: e342 issue: 7 year: 2015 ident: 109_CR75 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00077-7 – ident: 109_CR64 – volume: 141 start-page: 71 issue: 1 year: 2005 ident: 109_CR4 publication-title: Arch Dermatol doi: 10.1001/archderm.141.1.71 – volume: 19 start-page: 4589 issue: 17 year: 2013 ident: 109_CR59 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-0398 – volume: 172 start-page: 159 issue: 2 year: 2001 ident: 109_CR103 publication-title: Cancer Lett doi: 10.1016/S0304-3835(01)00648-6 – volume: 26 start-page: 1053 issue: 5 year: 2012 ident: 109_CR93 publication-title: Hematol Oncol Clin North Am doi: 10.1016/j.hoc.2012.07.006 – volume: 31 start-page: E1506 issue: 6 year: 2010 ident: 109_CR169 publication-title: Hum Mutat doi: 10.1002/humu.21271 – volume: 15 start-page: 290 issue: 5 year: 2015 ident: 109_CR47 publication-title: Nat Rev Cancer doi: 10.1038/nrc3911 – volume: 158A start-page: 3056 issue: 12 year: 2012 ident: 109_CR100 publication-title: Am J Med Genet A doi: 10.1002/ajmg.a.35550 – volume: 490 start-page: 61 issue: 7418 year: 2012 ident: 109_CR106 publication-title: Nature doi: 10.1038/nature11412 – volume: 44 start-page: 1006 issue: 9 year: 2012 ident: 109_CR50 publication-title: Nat Genet doi: 10.1038/ng.2359 – volume: 271 start-page: 16409 issue: 27 year: 1996 ident: 109_CR174 publication-title: J Biol Chem doi: 10.1074/jbc.271.27.16409 – volume: 44 start-page: 481 issue: 8 year: 2007 ident: 109_CR98 publication-title: J Med Genet doi: 10.1136/jmg.2007.049346 – volume: 104 start-page: 593 issue: 4 year: 2001 ident: 109_CR12 publication-title: Cell doi: 10.1016/S0092-8674(01)00245-8 – volume: 339 start-page: 237 issue: 2 year: 2013 ident: 109_CR118 publication-title: Cancer Lett doi: 10.1016/j.canlet.2013.06.014 – volume: 72 start-page: 2746 issue: 9 year: 1993 ident: 109_CR152 publication-title: Cancer doi: 10.1002/1097-0142(19931101)72:9<2746::AID-CNCR2820720936>3.0.CO;2-W – volume: 507 start-page: 315 issue: 7492 year: 2014 ident: 109_CR167 publication-title: Nature doi: 10.1038/nature12965 – volume: 44 start-page: 1111 issue: 10 year: 2012 ident: 109_CR76 publication-title: Nat Genet doi: 10.1038/ng.2405 – volume: 3 start-page: 118 issue: 2 year: 1993 ident: 109_CR48 publication-title: Nat Genet doi: 10.1038/ng0293-118 – volume: 46 start-page: 1227 issue: 11 year: 2014 ident: 109_CR96 publication-title: Nat Genet doi: 10.1038/ng.3095 – volume: 18 start-page: 4450 issue: 31 year: 1999 ident: 109_CR138 publication-title: Oncogene doi: 10.1038/sj.onc.1202829 – volume: 3 start-page: 350 issue: 3 year: 2013 ident: 109_CR53 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-12-0470 – volume: 487 start-page: 330 issue: 7407 year: 2012 ident: 109_CR143 publication-title: Nature doi: 10.1038/nature11252 – volume: 150 start-page: 251 issue: 2 year: 2012 ident: 109_CR51 publication-title: Cell doi: 10.1016/j.cell.2012.06.024 – volume: 124 start-page: 471 issue: 3 year: 2006 ident: 109_CR153 publication-title: Cell doi: 10.1016/j.cell.2006.01.016 – volume: 94 start-page: 225 issue: 1 year: 1999 ident: 109_CR80 publication-title: Blood doi: 10.1182/blood.V94.1.225.413k24_225_232 – volume: 110 start-page: 2910 issue: 8 year: 2013 ident: 109_CR157 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1213968110 – ident: 109_CR14 doi: 10.1159/000126561 – volume: 455 start-page: 1069 issue: 7216 year: 2008 ident: 109_CR65 publication-title: Nature doi: 10.1038/nature07423 – volume: 505 start-page: 495 issue: 7484 year: 2014 ident: 109_CR162 publication-title: Nature doi: 10.1038/nature12912 – volume: 4 start-page: 177 issue: 3 year: 2004 ident: 109_CR160 publication-title: Nat Rev Cancer doi: 10.1038/nrc1299 – volume: 44 start-page: 1104 issue: 10 year: 2012 ident: 109_CR77 publication-title: Nat Genet doi: 10.1038/ng.2396 – volume: 154 start-page: 755 issue: 3 year: 1999 ident: 109_CR148 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)65322-9 – volume: 32 start-page: 14087 issue: 41 year: 2012 ident: 109_CR21 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.3242-12.2012 – volume: 21 start-page: 5406 issue: 26 year: 2012 ident: 109_CR121 publication-title: Hum Mol Genet doi: 10.1093/hmg/dds402 – ident: 109_CR41 – volume: 109 start-page: 2730 issue: 8 year: 2012 ident: 109_CR111 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1018872108 – volume: 16 start-page: 4135 issue: 16 year: 2010 ident: 109_CR85 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-2639 – volume: 13 start-page: 229 issue: 3 year: 2012 ident: 109_CR37 publication-title: Neurogenetics doi: 10.1007/s10048-012-0332-y – volume: 7 start-page: 11908 year: 2016 ident: 109_CR108 publication-title: Nat Commun doi: 10.1038/ncomms11908 – volume: 20 start-page: C13 issue: 4 year: 2013 ident: 109_CR123 publication-title: Endocr Relat Cancer doi: 10.1530/ERC-13-0046 – volume: 3 start-page: 880 issue: 8 year: 2013 ident: 109_CR19 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-13-0146 – volume: 68 start-page: 820 issue: 4 year: 1971 ident: 109_CR10 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.68.4.820 – volume: 35 start-page: 43 issue: 1 year: 2001 ident: 109_CR119 publication-title: Endocr Regul – volume: 130 start-page: 554 issue: 3 year: 2013 ident: 109_CR180 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2013.06.019 – volume: 28 start-page: 1813 issue: 10 year: 2008 ident: 109_CR110 publication-title: Nan Fang Yi Ke Da Xue Xue Bao – volume: 6 start-page: l1 issue: 269 year: 2013 ident: 109_CR46 publication-title: Sci Signal – volume: 10 start-page: 1362 issue: 12 year: 2008 ident: 109_CR113 publication-title: Neoplasia doi: 10.1593/neo.08784 – volume: 458 start-page: 719 issue: 7239 year: 2009 ident: 109_CR40 publication-title: Nature doi: 10.1038/nature07943 – volume: 85 start-page: 318 issue: 4 year: 2014 ident: 109_CR26 publication-title: Clin Genet doi: 10.1111/cge.12187 – volume: 152A start-page: 1467 issue: 6 year: 2010 ident: 109_CR31 publication-title: Am J Med Genet A doi: 10.1002/ajmg.a.33386 – volume: 302 start-page: 2111 issue: 19 year: 2009 ident: 109_CR172 publication-title: JAMA doi: 10.1001/jama.2009.1663 – year: 2017 ident: 109_CR27 publication-title: Hum Genet doi: 10.1007/s00439-017-1779-6 – volume: 3 start-page: 62 issue: 1 year: 1993 ident: 109_CR129 publication-title: Nat Genet doi: 10.1038/ng0193-62 – volume: 6 start-page: 479 year: 2011 ident: 109_CR146 publication-title: Annu Rev Pathol doi: 10.1146/annurev-pathol-011110-130235 – volume: 1 start-page: 97 year: 2006 ident: 109_CR133 publication-title: Annu Rev Pathol doi: 10.1146/annurev.pathol.1.110304.100043 – volume: 483 start-page: 100 issue: 7387 year: 2012 ident: 109_CR165 publication-title: Nature doi: 10.1038/nature10868 – volume: 5 start-page: 3887 year: 2014 ident: 109_CR55 publication-title: Nat Commun doi: 10.1038/ncomms4887 – volume: 61 start-page: 69 issue: 2 year: 2011 ident: 109_CR69 publication-title: CA Cancer J Clin doi: 10.3322/caac.20107 – volume: 4 start-page: 606 issue: 5 year: 2014 ident: 109_CR71 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-13-0741 – ident: 109_CR161 – ident: 109_CR115 doi: 10.1371/journal.pone.0011408 – volume: 469 start-page: 343 issue: 7330 year: 2011 ident: 109_CR91 publication-title: Nature doi: 10.1038/nature09784 – volume: 486 start-page: 400 issue: 7403 year: 2012 ident: 109_CR102 publication-title: Nature doi: 10.1038/nature11017 – volume: 16 start-page: 5 issue: 1 year: 2016 ident: 109_CR164 publication-title: Nat Rev Cancer doi: 10.1038/nrc.2015.10 – volume: 10 start-page: 680 issue: 7 year: 2008 ident: 109_CR140 publication-title: Neoplasia doi: 10.1593/neo.08312 – volume: 4 start-page: 307 issue: 4 year: 2010 ident: 109_CR38 publication-title: Expert Opin Med Diagn doi: 10.1517/17530059.2010.494660 – volume: 205 start-page: 1 issue: 1-2 year: 2012 ident: 109_CR125 publication-title: Cancer Genet doi: 10.1016/j.cancergen.2012.01.009 – volume: 29 start-page: E173 issue: 9 year: 2008 ident: 109_CR30 publication-title: Hum Mutat doi: 10.1002/humu.20826 – volume: 5 start-page: 5893 year: 2014 ident: 109_CR73 publication-title: Nat Commun doi: 10.1038/ncomms6893 – volume: 2 start-page: 1034 issue: 11 year: 2011 ident: 109_CR131 publication-title: Genes Cancer doi: 10.1177/1947601912443127 – volume: 63 start-page: 1106 issue: 5 year: 2003 ident: 109_CR175 publication-title: Cancer Res – volume: 14 start-page: 257 year: 2013 ident: 109_CR56 publication-title: Annu Rev Genomics Hum Genet doi: 10.1146/annurev-genom-091212-153429 – start-page: 305 volume-title: Neurofibromatosis Type 1 year: 2012 ident: 109_CR16 doi: 10.1007/978-3-642-32864-0_20 – ident: 109_CR22 – volume: 107 start-page: 18545 issue: 43 year: 2010 ident: 109_CR155 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1010978107 – volume: 27 start-page: 10 issue: 1 year: 2013 ident: 109_CR94 publication-title: Leukemia doi: 10.1038/leu.2012.288 – volume: 102 start-page: 8573 issue: 24 year: 2005 ident: 109_CR17 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0503224102 – volume: 514 start-page: 247 issue: 7521 year: 2014 ident: 109_CR95 publication-title: Nature doi: 10.1038/nature13561 – volume: 314 start-page: 268 issue: 5797 year: 2006 ident: 109_CR101 publication-title: Science doi: 10.1126/science.1133427 – volume: 70 start-page: 813 issue: 5 year: 1994 ident: 109_CR141 publication-title: Br J Cancer doi: 10.1038/bjc.1994.404 – volume: 6 start-page: 21 issue: 1 year: 2007 ident: 109_CR23 publication-title: Fam Cancer doi: 10.1007/s10689-006-9001-3 – ident: 109_CR63 doi: 10.18632/oncotarget.16542 – volume: 488 start-page: 660 issue: 7413 year: 2012 ident: 109_CR145 publication-title: Nature doi: 10.1038/nature11282 – volume: 71 start-page: 1070 issue: 5 year: 1995 ident: 109_CR142 publication-title: Br J Cancer doi: 10.1038/bjc.1995.206 – ident: 109_CR43 – volume: 72 start-page: 1288 issue: 5 year: 2003 ident: 109_CR168 publication-title: Am J Hum Genet doi: 10.1086/374821 – volume: 62 start-page: 187 issue: 1 year: 1990 ident: 109_CR11 publication-title: Cell doi: 10.1016/0092-8674(90)90252-A – volume: 121 start-page: 1311 issue: 9 year: 2003 ident: 109_CR62 publication-title: Arch Ophthalmol doi: 10.1001/archopht.121.9.1311 – volume: 150 start-page: 1107 issue: 6 year: 2012 ident: 109_CR66 publication-title: Cell doi: 10.1016/j.cell.2012.08.029 – volume: 373 start-page: 1926 issue: 20 year: 2015 ident: 109_CR61 publication-title: N Engl J Med doi: 10.1056/NEJMoa1502583 – volume: 29 start-page: 4905 issue: 35 year: 2010 ident: 109_CR116 publication-title: Oncogene doi: 10.1038/onc.2010.245 – volume: 45 start-page: 927 issue: 8 year: 2013 ident: 109_CR135 publication-title: Nat Genet doi: 10.1038/ng.2682 – volume: 7 start-page: e38463 issue: 6 year: 2012 ident: 109_CR88 publication-title: PLoS One doi: 10.1371/journal.pone.0038463 – volume: 13 start-page: 1382 issue: 5 year: 2014 ident: 109_CR107 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-13-0482 – volume: 474 start-page: 609 issue: 7353 year: 2011 ident: 109_CR170 publication-title: Nature doi: 10.1038/nature10166 – volume: 26 start-page: 704 issue: 11 year: 1989 ident: 109_CR3 publication-title: J Med Genet doi: 10.1136/jmg.26.11.704 – volume: 16 start-page: 937 year: 2011 ident: 109_CR6 publication-title: Front Biosci (Landmark Ed) doi: 10.2741/3727 – volume: 90 start-page: 10914 issue: 23 year: 1993 ident: 109_CR151 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.90.23.10914 – volume: 74 start-page: 2340 issue: 8 year: 2014 ident: 109_CR52 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-2625 – volume: 42 start-page: 99 issue: 1 year: 2004 ident: 109_CR128 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.10381 – volume: 6 start-page: 313 issue: 4 year: 2004 ident: 109_CR57 publication-title: Cancer Cell doi: 10.1016/j.ccr.2004.09.022 – volume: 10 start-page: 508 issue: 5 year: 2009 ident: 109_CR9 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(09)70033-6 – ident: 109_CR42 – volume: 18 start-page: 382 issue: 3 year: 2012 ident: 109_CR70 publication-title: Nat Med doi: 10.1038/nm.2673 – volume: 142 start-page: 218 issue: 2 year: 2010 ident: 109_CR130 publication-title: Cell doi: 10.1016/j.cell.2010.06.004 – volume: 17 start-page: 98 issue: 1 year: 2010 ident: 109_CR136 publication-title: Cancer Cell doi: 10.1016/j.ccr.2009.12.020 – volume: 39 start-page: 1357 issue: 10 year: 2015 ident: 109_CR60 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000000451 – volume: 355 start-page: 752 issue: 6326 year: 2017 ident: 109_CR154 publication-title: Science doi: 10.1126/science.aai8690 – start-page: 115 volume-title: Neurofibromatosis Type 1 year: 2012 ident: 109_CR2 doi: 10.1007/978-3-642-32864-0_10 – volume: 11 start-page: 643 issue: 4 year: 2004 ident: 109_CR112 publication-title: Endocr Relat Cancer doi: 10.1677/erc.1.00776 – volume: 329 start-page: 699 issue: 4 year: 2003 ident: 109_CR173 publication-title: J Mol Biol doi: 10.1016/S0022-2836(03)00514-X – volume: 25 start-page: R123 issue: R2 year: 2016 ident: 109_CR39 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddw191 – volume: 18 start-page: 44 issue: 7 year: 2016 ident: 109_CR117 publication-title: Curr Oncol Rep doi: 10.1007/s11912-016-0526-9 – volume: 586 start-page: 2662 issue: 17 year: 2012 ident: 109_CR15 publication-title: FEBS Lett doi: 10.1016/j.febslet.2012.06.006 – volume: 321 start-page: 1807 issue: 5897 year: 2008 ident: 109_CR132 publication-title: Science doi: 10.1126/science.1164382 – volume: 339 start-page: 1546 issue: 6127 year: 2013 ident: 109_CR147 publication-title: Science doi: 10.1126/science.1235122 – volume: 455 start-page: 1061 issue: 7216 year: 2008 ident: 109_CR171 publication-title: Nature doi: 10.1038/nature07385 – volume: 2 start-page: 191 year: 2007 ident: 109_CR13 publication-title: Annu Rev Pathol doi: 10.1146/annurev.pathol.2.010506.091940 – volume: 192 start-page: 385 issue: 2 year: 2012 ident: 109_CR105 publication-title: Genetics doi: 10.1534/genetics.112.142802 – volume: 58 start-page: 484 issue: 3 year: 1996 ident: 109_CR32 publication-title: Am J Hum Genet – volume: 489 start-page: 519 issue: 7417 year: 2012 ident: 109_CR72 publication-title: Nature doi: 10.1038/nature11404 – volume: 7 start-page: 105 issue: 2 year: 2009 ident: 109_CR1 publication-title: J Pediatr Neurol – ident: 109_CR20 doi: 10.1111/exd.13212 – volume: 15 start-page: 541 issue: 6 year: 2000 ident: 109_CR24 publication-title: Hum Mutat doi: 10.1002/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N – volume: 22 start-page: 3148 issue: 13 year: 2016 ident: 109_CR68 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-2377 – volume: 33 start-page: 323 issue: 5 year: 2003 ident: 109_CR166 publication-title: Surg Today doi: 10.1007/s005950300074 – reference: 17143284 - Nat Genet. 2007 Jan;39(1):93-8 – reference: 23780408 - J Pathol. 2013 Sep;231(1):21-34 – reference: 10524872 - J Urol. 1999 Nov;162(5):1582-6 – reference: 23550210 - Sci Signal. 2013 Apr 02;6(269):pl1 – reference: 23539594 - Science. 2013 Mar 29;339(6127):1546-58 – reference: 2511318 - J Med Genet. 1989 Nov;26(11):704-11 – reference: 11566491 - Cancer Lett. 2001 Oct 30;172(2):159-64 – reference: 18772890 - Nature. 2008 Oct 23;455(7216):1061-8 – reference: 11239415 - Cell. 2001 Feb 23;104(4):593-604 – reference: 23009937 - Hematol Oncol Clin North Am. 2012 Oct;26(5):1053-64 – reference: 26149886 - Lancet Oncol. 2015 Jul;16(7):e342-51 – reference: 24535670 - Cancer Discov. 2014 May;4(5):606-19 – reference: 17960768 - Hum Mutat. 2008 Jan;29(1):74-82 – reference: 22842228 - Nat Genet. 2012 Sep;44(9):1006-14 – reference: 19710506 - Blood. 2009 Oct 22;114(17):3629-32 – reference: 21248841 - Nature. 2011 Jan 20;469(7330):343-9 – reference: 23061808 - Clin Endocrinol (Oxf). 2013 Feb;78(2):165-75 – reference: 28349240 - Hum Genet. 2017 Jun;136(6):665-677 – reference: 25661093 - Curr Opin Struct Biol. 2015 Jun;32:25-32 – reference: 23656349 - Clin Genet. 2014 Apr;85(4):318-27 – reference: 16944272 - Fam Cancer. 2007;6(1):21-34 – reference: 27412009 - Hum Mol Genet. 2016 Oct 1;25(R2):R123-R132 – reference: 18971180 - Nan Fang Yi Ke Da Xue Xue Bao. 2008 Oct;28(10):1813-5 – reference: 25531467 - Nat Commun. 2014 Dec 22;5:5893 – reference: 24120142 - Cell. 2013 Oct 10;155(2):462-77 – reference: 18592002 - Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 – reference: 21296855 - CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 – reference: 23661552 - Cancer Discov. 2013 Aug;3(8):880-93 – reference: 23875803 - Annu Rev Genomics Hum Genet. 2013;14:257-79 – reference: 7902574 - Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10914-21 – reference: 23288408 - Cancer Discov. 2013 Mar;3(3):350-62 – reference: 23010473 - Hum Mol Genet. 2012 Dec 15;21(26):5406-16 – reference: 20581869 - Oncogene. 2010 Sep 2;29(35):4905-13 – reference: 20655465 - Cell. 2010 Jul 23;142(2):218-29 – reference: 19048115 - Neoplasia. 2008 Dec;10(12):1362-72, following 1372 – reference: 16469695 - Cell. 2006 Feb 10;124(3):471-84 – reference: 26076063 - Am J Surg Pathol. 2015 Oct;39(10 ):1357-62 – reference: 7947085 - Br J Cancer. 1994 Nov;70(5):813-8 – reference: 19920235 - JAMA. 2009 Nov 18;302(19):2111-8 – reference: 23791886 - Cancer Lett. 2013 Oct 10;339(2):237-46 – reference: 8490657 - Nat Genet. 1993 Jan;3(1):62-6 – reference: 24978188 - J Clin Pathol. 2014 Sep;67(9):772-6 – reference: 22962301 - Hum Mol Genet. 2012 Dec 15;21(26):5397-405 – reference: 22960745 - Nature. 2012 Sep 27;489(7417):519-25 – reference: 20876136 - Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18545-50 – reference: 22728242 - FEBS Lett. 2012 Aug 14;586(17):2662-73 – reference: 16283621 - Genes Chromosomes Cancer. 2006 Mar;45(3):265-76 – reference: 15937108 - Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8 – reference: 7734302 - Br J Cancer. 1995 May;71(5):1070-3 – reference: 24576830 - Cancer Res. 2014 Apr 15;74(8):2340-50 – reference: 27322474 - EBioMedicine. 2016 May;7:212-20 – reference: 12734724 - Surg Today. 2003;33(5):323-7 – reference: 8499944 - Nat Genet. 1993 Feb;3(2):118-21 – reference: 8663212 - J Biol Chem. 1996 Jul 5;271(27):16409-15 – reference: 26861459 - Clin Cancer Res. 2016 Jul 1;22(13):3148-56 – reference: 22810696 - Nature. 2012 Jul 18;487(7407):330-7 – reference: 25629879 - Nat Commun. 2015 Jan 28;6:4852 – reference: 23887298 - Mod Pathol. 2014 Feb;27(2):271-80 – reference: 20513137 - Hum Mutat. 2010 Jun;31(6):E1506-18 – reference: 18772396 - Science. 2008 Sep 26;321(5897):1807-12 – reference: 23171796 - Cancer Discov. 2013 Mar;3(3):338-49 – reference: 23460398 - Am J Hematol. 2013 Apr;88(4):306-11 – reference: 17369502 - J Med Genet. 2007 Aug;44(8):481-4 – reference: 22281684 - Nature. 2012 Jan 26;483(7387):100-3 – reference: 27158780 - Nat Genet. 2016 Jun;48(6):607-16 – reference: 25877329 - Nat Rev Cancer. 2015 May;15(5):290-301 – reference: 23770567 - Nature. 2013 Jul 11;499(7457):214-8 – reference: 20668451 - Nature. 2010 Aug 12;466(7308):869-73 – reference: 22588877 - Cancer Discov. 2012 May;2(5):401-4 – reference: 16098465 - Cancer Cell. 2005 Aug;8(2):119-30 – reference: 7969279 - N Engl J Med. 1994 Nov 24;331(21):1403-7 – reference: 18039098 - Annu Rev Pathol. 2007;2:191-216 – reference: 23388632 - Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2910-5 – reference: 25277973 - Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15138-43 – reference: 18039109 - Annu Rev Pathol. 2006;1:97-117 – reference: 1694727 - Cell. 1990 Jul 13;62(1):187-92 – reference: 23496147 - Expert Opin Med Diagn. 2010 Jul;4(4):307-22 – reference: 21482774 - Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2730-5 – reference: 24390350 - Nature. 2014 Jan 23;505(7484):495-501 – reference: 15488754 - Cancer Cell. 2004 Oct;6(4):313-9 – reference: 10079253 - Am J Pathol. 1999 Mar;154(3):755-65 – reference: 12963615 - Arch Ophthalmol. 2003 Sep;121(9):1311-5 – reference: 28380455 - Oncotarget. 2017 Jun 20;8(25):40683-40692 – reference: 20129251 - Cancer Cell. 2010 Jan 19;17(1):98-110 – reference: 22941189 - Nat Genet. 2012 Oct;44(10):1111-6 – reference: 22200086 - Cancer Genet. 2011 Nov;204(11):603-28 – reference: 27241520 - Curr Oncol Rep. 2016 Jul;18(7):44 – reference: 10862084 - Hum Mutat. 2000;15(6):541-55 – reference: 27161491 - Nat Commun. 2016 May 10;7:11479 – reference: 14752801 - Pediatr Blood Cancer. 2004 Jan;42(1):99-105 – reference: 24608573 - Mol Cancer Ther. 2014 May;13(5):1382-9 – reference: 22941188 - Nat Genet. 2012 Oct;44(10 ):1104-10 – reference: 9180088 - N Engl J Med. 1997 Jun 12;336(24):1713-20 – reference: 27264733 - Nat Commun. 2016 Jun 06;7:11908 – reference: 21280148 - Hum Mutat. 2011 Feb;32(2):213-9 – reference: 21720365 - Nature. 2011 Jun 29;474(7353):609-15 – reference: 26667852 - Nat Rev Cancer. 2016 Jan;16(1):5 – reference: 17161157 - Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 – reference: 18413813 - Clin Cancer Res. 2008 Apr 15;14(8):2249-52 – reference: 5279523 - Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 – reference: 14993899 - Nat Rev Cancer. 2004 Mar;4(3):177-83 – reference: 16786042 - Br J Cancer. 2006 Jul 17;95(2):233-8 – reference: 23055477 - J Neurosci. 2012 Oct 10;32(41):14087-93 – reference: 21196210 - Front Biosci (Landmark Ed). 2011 Jan 01;16:937-51 – reference: 9209448 - Leukemia. 1997 Apr;11 Suppl 3:533-5 – reference: 11308996 - Endocr Regul. 2001 Mar;35(1):43-52 – reference: 27622733 - Exp Dermatol. 2016 Sep 13;:null – reference: 24871328 - Nat Commun. 2014 May 29;5:3887 – reference: 23165953 - Am J Med Genet A. 2012 Dec;158A(12 ):3056-60 – reference: 22015770 - Leukemia. 2012 Apr;26(4):834-9 – reference: 15655144 - Arch Dermatol. 2005 Jan;141(1):71-4 – reference: 19360079 - Nature. 2009 Apr 9;458(7239):719-24 – reference: 24132290 - Nature. 2013 Oct 17;502(7471):333-9 – reference: 23077663 - PLoS One. 2012;7(10):e47717 – reference: 16288202 - Oncogene. 2006 Apr 13;25(16):2297-303 – reference: 20345245 - Annu Rev Neurosci. 2010;33:221-43 – reference: 26457647 - Nat Genet. 2015 Nov;47(11):1326-33 – reference: 8644707 - Am J Hum Genet. 1996 Mar;58(3):484-90 – reference: 25119042 - Nature. 2014 Oct 9;514(7521):247-51 – reference: 23817572 - Nat Genet. 2013 Aug;45(8):927-32 – reference: 12660952 - Am J Hum Genet. 2003 May;72(5):1288-92 – reference: 22895193 - Nature. 2012 Aug 30;488(7413):660-4 – reference: 22807134 - Hum Mutat. 2012 Dec;33(12):1687-96 – reference: 21504710 - Cancer Genet. 2011 Mar;204(3):113-21 – reference: 21090969 - Annu Rev Pathol. 2011;6:479-507 – reference: 27760322 - Cell Rep. 2016 Oct 18;17 (4):1206 – reference: 26828429 - PLoS Comput Biol. 2016 Feb 01;12(2):e1004731 – reference: 22817889 - Cell. 2012 Jul 20;150(2):251-63 – reference: 12787671 - J Mol Biol. 2003 Jun 13;329(4):699-710 – reference: 22675565 - PLoS One. 2012;7(6):e38463 – reference: 22851646 - Genetics. 2012 Oct;192(2):385-96 – reference: 20505189 - Clin Cancer Res. 2010 Aug 15;16(16):4135-47 – reference: 20503322 - Am J Med Genet A. 2010 Jun;152A(6):1467-73 – reference: 22980975 - Cell. 2012 Sep 14;150(6):1107-20 – reference: 26457648 - Nat Genet. 2015 Nov;47(11):1334-40 – reference: 26559571 - N Engl J Med. 2015 Nov 12;373(20):1926-36 – reference: 15613444 - Endocr Relat Cancer. 2004 Dec;11(4):643-58 – reference: 18948947 - Nature. 2008 Oct 23;455(7216):1069-75 – reference: 24476821 - Nature. 2014 Mar 20;507(7492):315-22 – reference: 26214590 - Nat Genet. 2015 Sep;47(9):996-1002 – reference: 28209900 - Science. 2017 Feb 17;355(6326):752-756 – reference: 23756430 - Endocr Relat Cancer. 2013 Jul 04;20(4):C13-7 – reference: 25240281 - Nat Genet. 2014 Nov;46(11):1227-32 – reference: 23000897 - Nature. 2012 Oct 4;490(7418):61-70 – reference: 23791828 - Gynecol Oncol. 2013 Sep;130(3):554-9 – reference: 22429592 - Cancer Genet. 2012 Jan-Feb;205(1-2):1-11 – reference: 16959974 - Science. 2006 Oct 13;314(5797):268-74 – reference: 25079552 - Nature. 2014 Jul 31;511(7511):543-50 – reference: 22737269 - Genes Cancer. 2011 Nov;2(11):1034-43 – reference: 21115163 - Best Pract Res Clin Endocrinol Metab. 2010 Dec;24(6):943-56 – reference: 8402499 - Cancer. 1993 Nov 1;72(9):2746-54 – reference: 3105405 - Ann N Y Acad Sci. 1986;486:57-65 – reference: 22581253 - Neurogenetics. 2012 Aug;13(3):229-36 – reference: 10381517 - Blood. 1999 Jul 1;94(1):225-32 – reference: 19410195 - Lancet Oncol. 2009 May;10(5):508-15 – reference: 24448499 - Nat Commun. 2014;5:3156 – reference: 17160901 - Am J Hum Genet. 2007 Jan;80(1):140-51 – reference: 18546366 - Hum Mutat. 2008 Sep;29(9):E173-93 – reference: 23833303 - Clin Cancer Res. 2013 Sep 1;19(17):4589-98 – reference: 12615729 - Cancer Res. 2003 Mar 1;63(5):1106-13 – reference: 20543202 - J Med Genet. 2010 Sep;47(9):623-30 – reference: 21694737 - Eur J Hum Genet. 2011 Nov;19(11):1187-91 – reference: 10442636 - Oncogene. 1999 Aug 5;18(31):4450-9 – reference: 22327622 - Nat Med. 2012 Feb 12;18(3):382-4 – reference: 18172006 - Blood. 2008 Apr 15;111(8):4322-8 – reference: 22722201 - Nature. 2012 May 16;486(7403):400-4 – reference: 20844748 - PLoS One. 2010 Sep 10;5(9):null – reference: 23147254 - Leukemia. 2013 Jan;27(1):10-5 |
| SSID | ssj0031374 |
| Score | 2.5368211 |
| SecondaryResourceType | review_article |
| Snippet | Neurofibromatosis type 1 (NF1: Online Mendelian Inheritance in Man (OMIM) #162200) is an autosomal dominantly inherited tumour predisposition syndrome.... Background Neurofibromatosis type 1 (NF1: Online Mendelian Inheritance in Man (OMIM) #162200) is an autosomal dominantly inherited tumour predisposition... Abstract Background Neurofibromatosis type 1 (NF1: Online Mendelian Inheritance in Man (OMIM) #162200) is an autosomal dominantly inherited tumour... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 13 |
| SubjectTerms | Benign Brain cancer Breast cancer Cancer Drug resistance Epidermal growth factor receptors Genes Genes, Neurofibromatosis 1 Genetic disorders Genomes Glioblastoma Heredity Humans Kinases Leukemia Lung cancer Lung cancers Lung carcinoma Malignancy MAP kinase Melanoma Mutation Neoplasia Neoplasms - genetics Neoplasms - pathology Neuroblastoma Neuroendocrine tumors Neurofibromatosis Neurofibromatosis 1 - genetics Neurofibromatosis 1 - pathology Neurofibromin 1 Neurological disorders NF1 Ovarian cancer Ovarian carcinoma Proteins Recklinghausen's disease Retinoic acid Review Skin Skin cancer Somatic mutations Sporadic tumours Tumors |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Na90wDDelUNhlbN1XtrZ40FMhNLZj2b4U2tJHGaynFnoztuOwwpY3-t479L-f5OQ9-sbYLruEEMtgS7ItWcpPjB13kJMwmfC0Y8BH6GvbaV33ugPrcna6XF18vYHru_bLvb5_VuqLcsJGeOCRcaehl8FGmQUFwGIDMaZOKNtH6QoUPO2-eOatnalxD1ZCmXaKYQoLpwv0klrynCnNkoL9W6dQAev_k4X5e6Lks5Nn9oq9nExGfj4O9TXbycM-2xuLSD69YWcoaX4zE3wxL_Cr_MdqOd3w8fIjL6U48YeBkwMbOiQodfl4Ink_Lt6yu9nV7eV1PVVFqBNAs6yTc8k10aGrpJywiQBeXJZdguykDvgmbY9WXgalOjCyibE3EpLVpg9tSOod2x3mQ_7AuCDwMmnQyuhMa1MMVvdGYbeAyzhnqFiz5pJPE2Q4Va747ovrYMGPjPXIWE-M9apiJ5suP0e8jL8RXxDrN4QEdV0-oAL4SQH8vxSgYgdrwflp_S08eqFopyoFOIfPm2ZcORQOCUOerwoN4aeBlhV7P8p5MxJpgXB5TMXMlgZsDXW7ZXj4VtC5CUAPjaaP_2Nun9gLWZQWaikO2O7ycZUP0QhaxqOi778AWZgBsA priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Li9UwFD7oiOBGfFsdpYIroUyTNK-NouJlEJyVA3cX8qoOOO14e-_Cf29Omlu9IrMppUkgnEdyXv0OwOsgoicyIp62s-lh-0YFzpueB6F0jJrn0MWXM3F63n1e83UJuE2lrHJ_JuaDOoweY-Qnya9IlgdjQry7-tlg1yjMrpYWGjfhFkKXYUmXXC8OFyMsozCTTrJG846WrCZR4mRKflOHvjQWXmL6_-BeyvD9_7M5_y2d_OsuWt2Du8WIrN_PXL8PN-LwAG7PbSV_PYS3iff12YrU05gBWevL3bbE_Or8ay8WPdUXQ40urQ1pQu7UV3uUgM30CM5Xn75-PG1Kn4TGC9FuG6-1163TyXlimiiPkC860uBF1JTb9EZVn-y-mMgXhKStc72kwisue9tZzx7D0TAO8SnUBOHMqEx2R5Cd8s4q3kuWltmk2DGKCto9lYwvIOLYy-KHyc6EEmYmrEmENUhYwyp4syy5mhE0rpv8AUm_TETw6_xh3HwzRZeM7alVjkaCOVHXCud8IEz1jurcHaCC4z3jTNHIyfyRnwpeLcNJlzBBYoc47vIcRFQTnFbwZObzshOqBCL1yArkgQQcbPVwZLj4nvG6EVIvmVHPrt_Wc7hDsziKhpJjONpudvFFMni27mWW6t87tfsd priority: 102 providerName: ProQuest |
| Title | The NF1 somatic mutational landscape in sporadic human cancers |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28637487 https://www.proquest.com/docview/1915663366 https://www.proquest.com/docview/1912612652 https://pubmed.ncbi.nlm.nih.gov/PMC5480124 https://doaj.org/article/af2a8b2e15014b06bbcd138fb2908481 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEB_uA8EX8dvquVTwSai2SZuPBxVXbjmEW-RwYfElJGl6Hpxd3Q_w_ntn0m5xZRF8KaWZlPSXGTKTSX8D8LIWwRcyEJ-2s3ixTabqqsqaqhZKh6CruHVxPhVns_LTvJofwLa8VQ_gam9oR_WkZsvr179-3rxHg38bDV6JNyuMgUqKi-kQJaXyD-EYFyZJdnpeDkkFXvBIylyUUmeSi7JPcu59xc4yFdn897mgf5-k_GNpmtyFO71PmX7olOAeHIT2PtzqqkzePIB3qArpdFKkq0XkZ02_b9b9FmAa__SlM1DpVZsSDLZGgVi4L_WkEMvVQ5hNTr98PMv6sgmZFyJfZ15rr3OnMZbiulCeGGB0YLUXQbPK4h1TDbqBQXBeC8ly5xrJhFeVbGxpPX8ER-2iDU8gLYjdjEl0Q2pZKu-sqhrJsZtFOw9BJJBvUTK-5xSn0hbXJsYWSpgOWIPAGgLW8AReDV1-dIQa_xIeE_SDIHFhxweL5aXpTcvYhlnlWCgoRepy4ZyvC64ax3QsFpDAyXbizFa_DIap6MhyLvAbXgzNaFqUL7FtWGyiDBGsiYol8Lib52EkTAki7pEJyB0N2Bnqbkt79S3SdxPDHnpVT_8HiGdwm0XlFBkrTuBovdyE5-gNrd0IDuVcjuB4fDr9fDGKewqjqPd4vRh__Q25mQYv |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9QwDLfGTQheEP8pDCgSvCBVa5M2TR4AMdjpxrYTQpu0t5CkKUyC3rjeCe1L8Rmx0_bgENrbXqqqcdrIcVw7dn4GeF4J77LSE562NXgxdSKrokjqohJSea-KsHVxOBWT4_zDSXGyAb-GszCUVjnoxKCoq5mjPfJt9CvQ8uBciDdnPxKqGkXR1aGERicW-_78J7ps7au99zi_Lxgb7x69myR9VYHECZEuEqeUU6lV6GpwlUlHACnKs8oJr1hh8I7JGq0kjx-rRMlSa-uSCSeLsja5cRzfewU2c46uzAg2d3anHz8Nup9nPOA-Z3nJE1XkrI-jZlJst-ip5eS9U6onJRys_QlDwYD_Wbn_Jmv-9fcb34Qbvdkav-3k7BZs-OY2XO0KWZ7fgdcobfF0nMXtLEDAxt-Xi36XMQ6HiSnNKj5tYnKiTYUEoTZg7Ejm5u1dOL4UHt6DUTNr_AOIMwJQYyVaOlWZS2eNLOqSYzeDqsR7EUE6cEm7Hracqmd808F9kUJ3jNXIWE2M1TyCl6suZx1mx0XEO8T6FSHBbYcHs_kX3a9ebWpmpGU-oyisTYW1rsq4rC1ToR5BBFvDxOleB7T6j8RG8GzVjKuXQjKm8bNloCEMN1GwCO5387waCZOCsIHKCMo1CVgb6npLc_o1IIQTiB8abg8vHtZTuDY5OjzQB3vT_UdwnQXRFAnLtmC0mC_9YzS3FvZJL-MxfL7sZfUbwE84rw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlAviDeBAkGCC1K0azt-HQABZdVSWHGg0t6M7ThQqWTLPoT61_h1eJwHLEK99RJF8TixxjOTGXv8DcDTSgRPZEA8bWfjxdaFqjgval4JpUPQPC1dfJyK_aPy_YzPtuBXfxYG0yp7m5gMdTX3uEY-inFF9DwYE2JUd2kRn_Ymr05_FFhBCnda-3IarYgchrOfMXxbvjjYi3P9jNLJu89v94uuwkDhhRivCq-112OnY9jBNFEewVJ0oJUXQVNu4x1VdfSYQvxwJSQdO1dLKrzisral9Sy-9xJclowT1DE5G4I9RlhCgCalZIXmJe12VIkSo2WM2UqM4zHpE1MPNv6JqXTA__zdf9M2__oPTq7Dtc6BzV-3EncDtkJzE660JS3PbsHLKHf5dELy5TyBwebf16tuvTFPx4ox4So_bnIMp20VCVKVwNyj9C2Wt-HoQjh4B7abeRPuQU4QSo3K6PNUslTeWcVryWI3G41KCCKDcc8l4zsAc6yjcWJSIKOEaRlrImMNMtawDJ4PXU5b9I7ziN8g6wdCBN5OD-aLr6bTY2NrapWjgeB-rBsL53xFmKod1akyQQa7_cSZzhoszR_ZzeDJ0Bz1GDdnbBPm60SDaG6C0wzutvM8jIQqgShBMgO5IQEbQ91saY6_JaxwhPOLLtz984f1GK5GZTIfDqaHD2CHJskUBSW7sL1arMPD6Het3KMk4Dl8uWiN-g0WGTt_ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+NF1+somatic+mutational+landscape+in+sporadic+human+cancers&rft.jtitle=Human+genomics&rft.au=Philpott%2C+Charlotte&rft.au=Tovell%2C+Hannah&rft.au=Frayling%2C+Ian+M.&rft.au=Cooper%2C+David+N.&rft.date=2017-06-21&rft.issn=1479-7364&rft.eissn=1479-7364&rft.volume=11&rft.issue=1&rft_id=info:doi/10.1186%2Fs40246-017-0109-3&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s40246_017_0109_3 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-7364&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-7364&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-7364&client=summon |